The Motley Fool··Prosper Junior BakinyMorgan Stanley Sees 52% Upside for Eli Lilly as Weight-Loss Drugs Reshape Revenue
Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.
LLYCVSNVOweight loss drugsZepbound